Catalent's OSDrC OptiDose enables the design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement within the tablet.
Catalent’s OSDrC® OptiDose™ enables design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement. The flexible-core capability provides new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing processes. This expands tableting capabilities in many areas that differentiate beyond existing technologies.
OptiDose technology provides the flexibility to design single or multiple API in a single tablet, with different release profiles. In addition to shown improvement in mass variability between layers, OptiDose also offers tablet design to minimize cross-layer interaction of API and improved product stability.
One of the more recognized approaches for developing high quality controlled release formulations, Wurster fluid bed technology is a bottom-spray approach, where a coating medium is sprayed onto the particle. Compared to alternative technologies, it produces a more consistent coating for powders, granules, pellets, and micro-tablets, with higher quality controlled release product due to more predictable residence time within the coating zone.
Catalent recently invested in major capacity expansions at its Schorndorf, Germany; Somerset, NJ; and Winchester, KY, facilities to increase fluid bed capacity and capabilities to meet growing customer demand.
Company name: Catalent Pharma Solutions
Website: www.catalent.com
E-mail: info@catalent.com
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.